137058-17-4

Upstream product

• 121-98-2 methyl 4-methoxybenzoate 
• 67-56-1 methanol 
• 95233-12-8 4-methoxycyclohexylcarboxylic acid 

Downstream Products

• 95233-12-8 4-methoxycyclohexylcarboxylic acid 
• 101869-74-3 (4-methoxy-cyclohexyl)-methanol 
• 213915-20-9 cis-1-benzyloxymethyl-4-methoxycyclohexanecarboxylic acid 
• 306948-20-9 3-(2,6-dimethyl-phenyl)-4-hydroxy-8-methoxy-1-methoxymethoxy-1-aza-spiro[4.5]dec-3-en-2-one 
• 306948-19-6 3-(2,6-dimethyl-phenyl)-4-hydroxy-1,8-dimethoxy-1-aza-spiro[4.5]dec-3-en-2-one 
• 73873-64-0 Methyl 1-methyl-trans-4-methoxycyclohexanecarboxylate 
• 73873-66-2 methyl 1-methyl-cis-4-methoxycyclohexanecarboxylate 
• 73873-59-3 4-methoxycyclohexanecarboxylic acid 
• 73873-61-7 trans-4-methoxycyclohexane-1-carboxylic acid 
• 596806-86-9 methyl 1-[hydroxy(mesitylacetyl)amino]-4-methoxycyclohexanecarboxylate 

Relevant academic research and scientific papers

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Synthesis, structure, and SAR of tetrahydropyran-based LpxC inhibitors

In the search for novel Gram-negative agents, we performed a comprehensive search of the AstraZeneca collection and identified a tetrahydropyran-based matrix metalloprotease (MMP) inhibitor that demonstrated nanomolar inhibition of UDP-3-O-(acyl)-N-acetylglucosamine deacetylase (LpxC). Crystallographic studies in Aquifex aeolicus LpxC indicated the tetrahydropyran engaged in the same hydrogen bonds and van der Waals interactions as other known inhibitors. Systematic optimization of three locales on the scaffold provided compounds with improved Gram-negative activity. However, the optimization of LpxC activity was not accompanied by reduced inhibition of MMPs. Comparison of the crystal structure of the native product, UDP-3-O-(acyl)-glucosamine, in Aquifex aeolicus to the structure of a tetrahydropyran-based inhibitor indicates pathways for future optimization.

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.

Stereochemistry of Alkylation of Carboxylic Acid Salt and Ester α Anions Derived from Cyclic Systems.

A stereochemical study of the alkylation of α-lithiated carboxylate salts and esters has been performed.The α anions derived from the bicyclic acids exo-1, endo-1, and 7 (R=H) and the esters 4 and 7 (R=CH3) yield predominantly exo alkylation.As an example, the α anion derived from ester 7 (R=CH3) on treatment with CH3I yields exo-8 (R=R'=CH3) and endo-9 (R=R'=CH3) in a 97:3 ratio, a highly stereoselective reaction.Addition of TMEDA to the reactions involving the α anions derived from exo- or endo-1 did not change the stereochemical alkylation results.The α anions derived from the substituted cyclohexanecarboxylic acids 10, 13, 16, 19, or 22 (where R=H in each case) on methylation yield more axial methylation (axial/equatorial ratios of 0.4-2.7) than the α anions derived from the methyl esters corresponding to these acids.The α anions from the esters yield predominantly equatorial methylated products (e/a ratios varying from 4 to 9).The reasons for the different stereochemical results are discussed.